YAN LI¹, HUZHI CAI², XIAOLING PENG³, YOUHUI LIU⁴, QINGYANG CHEN⁴, XIANGDONG LIN⁵, XINYU CHEN^6,*

BIOCELL, Vol.48, No.3, pp. 501-511, 2024, DOI:10.32604/biocell.2023.030854

Abstract Background: Renal fibrosis is an important process in the development of chronic kidney disease. Understanding the pathogenesis and finding effective treatments for renal fibrosis is crucial. This study aims to investigate whether a newly discovered long non-coding RNA (lncRNA) called LOC103694972 could be a potential target for treating fibrosis of NRK-49F cells. Methods:: LncRNA Chip was used to identify differentially expressed lncRNAs between TGF-β1-induced NRK-49F cells and normal cells. The dual-luciferase assay confirmed the binding between miR-29c-3p and signal transducer and activator of transcription (STAT3), as well as between miR-29c-3p and lncRNA LOC103694972. Si-LOC103694972 and miR-29c-3p mimic were then transfected… More > Graphic Abstract

GIULIA CHIABOTTO^1,*, STEFANIA BRUNO^2,*

BIOCELL, Vol.47, No.7, pp. 1499-1508, 2023, DOI:10.32604/biocell.2023.028121

Abstract Renal fibrosis and inflammation are common pathological features of chronic kidney disease (CKD). Since currently available treatments can only delay the progression of CKD, the outcome of patients with CKD is still poor. One therapeutic option for the prevention of CKD-related complications could be the use of mesenchymal stromal cells (MSCs), which have shown beneficial effects in tissue fibrosis and regeneration after damage. However, safety issues, such as cellular rejection and carcinogenicity, limit their clinical application. Among the bioactive factors secreted by MSCs, extracellular vesicles (EVs) have shown the same beneficial effect of MSCs, without any notable side effects. This… More > Graphic Abstract